CD3e-immunotoxin spares CD62L(lo) Tregs and reshapes organ-specific T-cell composition by preferentially depleting CD3e(hi) T cells

• Published in: bioRxiv
• Main Authors: Kim, Shihyoung, Shukla, Rajni Kant, Yu, Hannah, Baek, Alice, Cressman, Sophie G, Golconda, Sarah, Lee, Ga-Eun, Choi, Hyewon, Reneau, John C, Wang, Zhirui, Huang, Christene A, Namal Pm Liyanage, Kim, Sanggu
• Format: Paper
• Language: English
• Published: Cold Spring Harbor Cold Spring Harbor Laboratory Press 25.07.2022
• Subjects: Autoimmunity; CD3 antigen; Foxp3 protein; Graft rejection; Immunotoxins; L-selectin; Lymph nodes; Lymphocytes; Lymphocytes T; Pharmacodynamics; Phenotypes
• DOI: 10.1101/2022.07.25.501205

CD3-epsilon(CD3e) immunotoxins (IT), a promising precision reagent for various clinical conditions requiring effective depletion of T cells, often shows limited treatment efficacy for largely unknown reasons. Tissue-resident T cells that persist in peripheral tissues have been shown to play pivotal roles in local and systemic immunity, as well as transplant rejection, autoimmunity and cancers. The impact of CD3e-IT treatment on these local cells, however, remains poorly understood. Here, using a new murine testing model, we demonstrate a substantial enrichment of tissue-resident Foxp3+ Tregs following CD3e-IT treatment. Differential surface expression of CD3e among T-cell subsets appears to be a main driver of Treg enrichment in CD3e-IT treatment. The surviving Tregs in CD3e-IT-treated mice were mostly the CD3edimCD62Llo effector phenotype, but the levels of this phenotype markedly varied among different lymphoid and nonlymphoid organs. We also found notable variations in surface CD3e levels among tissue-resident T cells of different organs, and these variations drive CD3e-IT to uniquely reshape T-cell compositions in local organs. The functions of organs and anatomic locations (lymph nodes) also affected the efficacy of CD3e-IT. The multi-organ pharmacodynamics of CD3e-IT and potential treatment resistance mechanisms identified in this study may generate new opportunities to further improve this promising treatment. Competing Interest Statement The authors have declared no competing interest.